RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
|Slideshows|February 2, 2016
Psychiatry Roundup: January
Author(s)Laurie Martin
Editors' picks, including the biggest story of the year thus far and others of interest to psychiatrists and the public.
Advertisement
References:
Stories mentioned in this slideshow
Advertisement
Related to this article
Discover how integrated psychotherapy—CBTp, family support, and relapse plans—boosts schizophrenia recovery alongside antipsychotics.
A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.
Medicare claims show pimavanserin in Parkinson psychosis nursing homes links to fewer falls and recurrent falls than quetiapine or other antipsychotics.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
2
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
3
Positive Phase 2 Topline Results: Remlifanserin for the Treatment of Alzheimer Disease Psychosis
4
The Adolescent Brain and Schizophrenia: What Research Reveals About Pruning, Dopamine, and Myelin
5